Cargando…
Human health risk assessment of pharmaceuticals in the European Vecht River
Active pharmaceutical ingredients (APIs) can reach surface waters used for drinking water extraction and recreational activities, such as swimming and fishing. The aim of the present study was to systematically assess the lifetime human health risks posed by 15 individual APIs and their mixtures occ...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790459/ https://www.ncbi.nlm.nih.gov/pubmed/35112470 http://dx.doi.org/10.1002/ieam.4588 |
_version_ | 1784859181852917760 |
---|---|
author | Duarte, Daniel J. Oldenkamp, Rik Ragas, Ad M. J. |
author_facet | Duarte, Daniel J. Oldenkamp, Rik Ragas, Ad M. J. |
author_sort | Duarte, Daniel J. |
collection | PubMed |
description | Active pharmaceutical ingredients (APIs) can reach surface waters used for drinking water extraction and recreational activities, such as swimming and fishing. The aim of the present study was to systematically assess the lifetime human health risks posed by 15 individual APIs and their mixtures occurring in the German–Dutch transboundary Vecht River. An exposure model was developed and used to assess the combined risks of oral and dermal exposure under a variety of exposure conditions. A total of 4500 API uptake values and 165 lifetime risk values were estimated for 15 and 11 APIs, respectively. Overall, the lifetime human health risks posed by the APIs and their mixtures based on modeling results were deemed acceptable under typical exposure conditions. Under very extreme environmental conditions and human behavior, API mixture risks were of potential concern while the risks of individual APIs were negligible, with a few exceptions. The antibiotic doxycycline and analgesic phenazone showed the highest and lowest risks, respectively. The study did not evaluate the potential risks caused by metabolite compounds. Recommendations for water managers are provided to help improve the accuracy and utility of human health risk assessments of pharmaceuticals. Integr Environ Assess Manag 2022;18:1639–1654. © 2022 The Authors. Integrated Environmental Assessment and Management published by Wiley Periodicals LLC on behalf of Society of Environmental Toxicology & Chemistry (SETAC). |
format | Online Article Text |
id | pubmed-9790459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97904592022-12-28 Human health risk assessment of pharmaceuticals in the European Vecht River Duarte, Daniel J. Oldenkamp, Rik Ragas, Ad M. J. Integr Environ Assess Manag Health & Ecological Risk Assessment Active pharmaceutical ingredients (APIs) can reach surface waters used for drinking water extraction and recreational activities, such as swimming and fishing. The aim of the present study was to systematically assess the lifetime human health risks posed by 15 individual APIs and their mixtures occurring in the German–Dutch transboundary Vecht River. An exposure model was developed and used to assess the combined risks of oral and dermal exposure under a variety of exposure conditions. A total of 4500 API uptake values and 165 lifetime risk values were estimated for 15 and 11 APIs, respectively. Overall, the lifetime human health risks posed by the APIs and their mixtures based on modeling results were deemed acceptable under typical exposure conditions. Under very extreme environmental conditions and human behavior, API mixture risks were of potential concern while the risks of individual APIs were negligible, with a few exceptions. The antibiotic doxycycline and analgesic phenazone showed the highest and lowest risks, respectively. The study did not evaluate the potential risks caused by metabolite compounds. Recommendations for water managers are provided to help improve the accuracy and utility of human health risk assessments of pharmaceuticals. Integr Environ Assess Manag 2022;18:1639–1654. © 2022 The Authors. Integrated Environmental Assessment and Management published by Wiley Periodicals LLC on behalf of Society of Environmental Toxicology & Chemistry (SETAC). John Wiley and Sons Inc. 2022-02-28 2022-11 /pmc/articles/PMC9790459/ /pubmed/35112470 http://dx.doi.org/10.1002/ieam.4588 Text en © 2022 The Authors. Integrated Environmental Assessment and Management published by Wiley Periodicals LLC on behalf of Society of Environmental Toxicology & Chemistry (SETAC) https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Health & Ecological Risk Assessment Duarte, Daniel J. Oldenkamp, Rik Ragas, Ad M. J. Human health risk assessment of pharmaceuticals in the European Vecht River |
title | Human health risk assessment of pharmaceuticals in the European Vecht River |
title_full | Human health risk assessment of pharmaceuticals in the European Vecht River |
title_fullStr | Human health risk assessment of pharmaceuticals in the European Vecht River |
title_full_unstemmed | Human health risk assessment of pharmaceuticals in the European Vecht River |
title_short | Human health risk assessment of pharmaceuticals in the European Vecht River |
title_sort | human health risk assessment of pharmaceuticals in the european vecht river |
topic | Health & Ecological Risk Assessment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790459/ https://www.ncbi.nlm.nih.gov/pubmed/35112470 http://dx.doi.org/10.1002/ieam.4588 |
work_keys_str_mv | AT duartedanielj humanhealthriskassessmentofpharmaceuticalsintheeuropeanvechtriver AT oldenkamprik humanhealthriskassessmentofpharmaceuticalsintheeuropeanvechtriver AT ragasadmj humanhealthriskassessmentofpharmaceuticalsintheeuropeanvechtriver |